[{"id":"f558dd72-ce2b-4a2b-8f9d-1822f6c0359b","acronym":"NCI-2014-02655","url":"https://clinicaltrials.gov/study/NCT01740557","created_at":"2021-01-18T07:37:08.655Z","updated_at":"2024-07-02T16:35:38.425Z","phase":"Phase 1/2","brief_title":"Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma","source_id_and_acronym":"NCT01740557 - NCI-2014-02655","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CXCL8 • NGFR • CXCR2","pipe":"","alterations":" ","tags":["CXCL8 • NGFR • CXCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CXCR2 and NGFR transduced TIL • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 01/28/2015","start_date":" 01/28/2015","primary_txt":" Primary completion: 04/21/2023","primary_completion_date":" 04/21/2023","study_txt":" Completion: 04/21/2023","study_completion_date":" 04/21/2023","last_update_posted":"2023-08-31"}]